Methods for treating obesity employing an SGLT2 inhibitor
View Patent ↗Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
1. A method for treating obesity in a mammalian subject or patient comprising administering to a mammalian subject or patient in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor having the structure
wherein
R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle which can contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 ;
R 3 and R 4 are independently hydrogen, OH, OR 5a , OAryl, OCH 2 Aryl, alkyl, cycloalkyl, CF 3 , —OCHF 2 , —OCF 3 , halogen, —CN, —CO 2 R 5b , —CO 2 H, COR 6b , —CH(OH)R 6c , —CH(OR 5h )R 6d , —CONR 6 R 6a , —NHCOR 5c , —NHSO 2 R 5d , —NHSO 2 Aryl, Aryl, —SR 5e , —SOR 5f , —SO 2 R 5g , —SO 2 Aryl, or a five, six or seven membered heterocycle which can contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 , or R 3 and R 4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which can contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 ;
R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h and R 5i are independently alkyl;
R 6 , R 6a , R 6b , R 6c , and R 6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which can contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 ;
A is O, S, NH, or (CH 2 ) n where n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof;
with the proviso that where A is (CH 2 ) n where n is 0, 1, 2, or 3 or A is O, and at least one of R 1 , R 2 , and R 2a is OH or OR 5 , then at least one of R 1 , R 2 , and R 2a is CF 3 , OCF 3 , or OCHF 2 and/or at least one of R 3 and R 4 is CF 3 , —OCHF 2 , —OCF 3 , —CN, —CO 2 R 5b , CH(OR 5h )R 6d , CH(OH)R 6c , COR 6b , —NHCOR 5c , —NHSO 2 R 5d , —NHSO 2 Aryl, Aryl, —SR 5e , —SOR 5f , —SO 2 R 5g or —SO 2 Aryl,
wherein the amount of the SGLT2 inhibitor does not cause a significant reduction in blood glucose levels in the mammalian subject or patient and does not cause hypoglycemia in the in the mammalian subject or patient.
2. The method according to claim 1 , wherein the mammal is a human.
3. The method according to claim 1 , wherein the mammal is a human with type II diabetes mellitus.
4. The method according to claim 1 , wherein the SGLT2 inhibitor has the structure
wherein
A is CH 2 ; R 1 is hydrogen, halogen or lower alkyl; R 2 and R 2a are each H; R 3 is H; R 4 is lower alkyl, —COR 6b , —CH(OH)R 6c , —CH(OR 5h )R 6d , R 5a O, —OCHF 2 , —OCF 3 or —SR 5e .
5. The method according to claim 1 , wherein the SGLT2 inhibitor has the structure
or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a prodrug ester thereof.
6. The method according to claim 1 , wherein the SGLT2 inhibitor has the structure
7. The method according to claim 1 , wherein the SGLT2 inhibitor is dapagliflozin provided as a propylene glycol hydrate.